LPCN Lipocine Inc.

0.43
+0.01  (+4%)
Previous Close 0.42
Open 0.42
Price To Book 3.31
Market Cap 20,577,435
Shares 47,854,499
Volume 308,434
Short Ratio
Av. Daily Volume 1,337,932
Stock charts supplied by TradingView

NewsSee all news

  1. Lipocine Announces Outcome of Markman Hearing in Patent Infringement Suit Against Clarus

    SALT LAKE CITY, March 26, 2020 /PRNewswire/ -- Lipocine Inc. (NASDAQ:LPCN), a clinical-stage biopharmaceutical company focused on metabolic and endocrine disorders, today announced that Judge William C. Bryson of the

  2. Lipocine Announces 2019 Year End Financial and Operational Results

    SALT LAKE CITY, March 13, 2020 /PRNewswire/ -- Lipocine Inc. (NASDAQ:LPCN), a clinical-stage biopharmaceutical company, today announced financial results for the year ended December 31, 2019, and provided a corporate

  3. Lipocine Announces TLANDO™ PDUFA Date of August 28, 2020

    SALT LAKE CITY, March 4, 2020 /PRNewswire/ -- Lipocine Inc. (NASDAQ:LPCN), a clinical-stage biopharmaceutical company, announced today that the U.S. Food and Drug Administration ("FDA") acknowledged receipt of

  4. Lipocine Announces Closing Of Registered Direct Offering Of Common Stock And Warrants

    SALT LAKE CITY, Feb. 27, 2020 /PRNewswire/ -- Lipocine Inc. (NASDAQ:LPCN), a clinical-stage biopharmaceutical company focused on metabolic and endocrine disorders, today announced the closing of a registered direct

  5. Lipocine Announces $6 Million Registered Direct Offering Priced At-The-Market

    SALT LAKE CITY, Feb. 25, 2020 /PRNewswire/ -- Lipocine Inc. (NASDAQ:LPCN), a clinical-stage biopharmaceutical company focused on metabolic and endocrine disorders, today announced that it has entered into securities

Drug Information

Drug catalyst information is displayed when you hover over / tap on the stage bar graph.

Phase 2b top-line data released September 2016. Seeking feedback from FDA regarding Phase 3 design.
LPCN 1111
Oral testosterone product
PDUFA date August 28, 2020
TLANDO - LPCN 1021
Men with low testosterone (Low T)
Conduct food/fact effect study in preparation for Phase 3 trial.
LPCN 1107
Prevention of preterm birth ("PTB").
Phase 2 top-line data due 2H 2020.
LPCN 1144
Non-alcoholic fatty liver disease (NAFLD) / Non-alcoholic steatohepatitis (NASH)

Latest News

  1. Lipocine Announces Outcome of Markman Hearing in Patent Infringement Suit Against Clarus

    SALT LAKE CITY, March 26, 2020 /PRNewswire/ -- Lipocine Inc. (NASDAQ:LPCN), a clinical-stage biopharmaceutical company focused on metabolic and endocrine disorders, today announced that Judge William C. Bryson of the

  2. Lipocine Announces 2019 Year End Financial and Operational Results

    SALT LAKE CITY, March 13, 2020 /PRNewswire/ -- Lipocine Inc. (NASDAQ:LPCN), a clinical-stage biopharmaceutical company, today announced financial results for the year ended December 31, 2019, and provided a corporate

  3. Lipocine Announces TLANDO™ PDUFA Date of August 28, 2020

    SALT LAKE CITY, March 4, 2020 /PRNewswire/ -- Lipocine Inc. (NASDAQ:LPCN), a clinical-stage biopharmaceutical company, announced today that the U.S. Food and Drug Administration ("FDA") acknowledged receipt of

  4. Lipocine Announces Closing Of Registered Direct Offering Of Common Stock And Warrants

    SALT LAKE CITY, Feb. 27, 2020 /PRNewswire/ -- Lipocine Inc. (NASDAQ:LPCN), a clinical-stage biopharmaceutical company focused on metabolic and endocrine disorders, today announced the closing of a registered direct

  5. Lipocine Announces $6 Million Registered Direct Offering Priced At-The-Market

    SALT LAKE CITY, Feb. 25, 2020 /PRNewswire/ -- Lipocine Inc. (NASDAQ:LPCN), a clinical-stage biopharmaceutical company focused on metabolic and endocrine disorders, today announced that it has entered into securities

  6. Lipocine Announces Regulatory Path Forward for TLANDO™ Resubmission

    SALT LAKE CITY, Feb. 24, 2020 /PRNewswire/ -- Lipocine Inc. (LPCN), a clinical-stage biopharmaceutical company focused on metabolic and endocrine disorders, today announced the results of its Post Action meeting with the

  7. Lipocine Streamlines Its Infringement Lawsuit Against Clarus Therapeutics

    SALT LAKE CITY, Feb. 11, 2020 /PRNewswire/ -- Lipocine Inc. (NASDAQ:LPCN), a clinical-stage biopharmaceutical company, announced today that in an effort to streamline the issues and associated costs for dispute in its

  8. Lipocine Announces Closing Of Public Offering Of Common Stock And Warrants

    SALT LAKE CITY, Nov. 18, 2019 /PRNewswire/ -- Lipocine Inc. (NASDAQ:LPCN), a clinical-stage biopharmaceutical company focused on metabolic and endocrine disorders, today announced the closing of a public offering of (i)

  9. Lipocine Announces Pricing Of Public Offering Of Common Stock And Warrants

    SALT LAKE CITY, Nov. 14, 2019 /PRNewswire/ -- Lipocine Inc. (NASDAQ:LPCN), a clinical-stage biopharmaceutical company focused on metabolic and endocrine disorders, today announced the pricing of a public

  10. Lipocine Announces Launch Of Public Offering Of Common Stock And Warrants

    SALT LAKE CITY, Nov. 13, 2019 /PRNewswire/ -- Lipocine Inc. (NASDAQ:LPCN), a clinical-stage biopharmaceutical company focused on metabolic and endocrine disorders, today announced the launch of a public offering of units

  11. Lipocine Announces Third Quarter 2019 Financial and Operational Results

    SALT LAKE CITY, Nov. 12, 2019 /PRNewswire/ -- Lipocine Inc. (NASDAQ:LPCN), a clinical-stage biopharmaceutical company, today announced financial results for the third quarter and nine months ended September 30, 2019, and

  12. Lipocine Receives Complete Response Letter for TLANDO™ from U.S. FDA

    SALT LAKE CITY, Nov. 11, 2019 /PRNewswire/ -- Lipocine Inc. (NASDAQ:LPCN), a clinical-stage biopharmaceutical company, announced today that it has received a Complete Response Letter ("CRL") from the United

  13. Lipocine to Present at the B. Riley NASH Symposium

    SALT LAKE CITY, Oct. 14, 2019 /PRNewswire/ -- Lipocine Inc. (NASDAQ:LPCN), clinical-stage biopharmaceutical company, announced today that Dr. Mahesh Patel, Chairman, President and CEO, will participate in a panel

  14. Lipocine to Present at the H.C. Wainwright 3rd Annual NASH Investor Conference

    SALT LAKE CITY, Oct. 10, 2019 /PRNewswire/ -- Lipocine Inc. (NASDAQ:LPCN), clinical-stage biopharmaceutical company, announced today that Dr. Mahesh Patel, Chairman, President and CEO, will provide a corporate overview

  15. Lipocine To Present LPCN 1144 Poster Of Distinction At The Liver Meeting® 2019

    SALT LAKE CITY, Oct. 1, 2019 /PRNewswire/ -- Lipocine Inc. (NASDAQ:LPCN), a clinical-stage biopharmaceutical company focused on metabolic and endocrine disorders, announced today that data from a clinical trial of LPCN

  16. First Biopsy Confirmed Nash Patient Dosed In Lipocine LiFT Study Of LPCN 1144

    SALT LAKE CITY, Sept. 30, 2019 /PRNewswire/ -- Lipocine Inc. (NASDAQ:LPCN), a clinical-stage biopharmaceutical company focused on metabolic and endocrine disorders, today announced that the first patient has been dosed

  17. Lipocine Announces Presentations at the 20th Annual Fall Meeting of the Sexual Medicine Society of North America

    SALT LAKE CITY, Sept. 23, 2019 /PRNewswire/ -- Lipocine Inc. (NASDAQ:LPCN), a clinical-stage biopharmaceutical company focused on metabolic and endocrine disorders, today announced that four abstracts (two oral

  18. Lipocine to Present at the Ladenburg Thalmann 2019 Healthcare Conference

    SALT LAKE CITY, Sept. 17, 2019 /PRNewswire/ -- Lipocine Inc. (NASDAQ:LPCN), a clinical-stage biopharmaceutical company focused on metabolic and endocrine disorders, announced today that Dr. Mahesh Patel, Chairman,

  19. Lipocine to Participate in the Oppenheimer & Co. Fall Summit Focused on Specialty Pharma, Rare Disease & Gene Therapy

    SALT LAKE CITY, Sept. 16, 2019 /PRNewswire/ -- Lipocine Inc. (NASDAQ:LPCN), a clinical-stage biopharmaceutical company focused on metabolic and endocrine disorders, announced today that Dr. Mahesh Patel, Chairman,

  20. Lipocine Announces Trial Date in Lipocine's Infringement Lawsuit Against Clarus Therapeutics and Will Seek a Permanent Injunction

    SALT LAKE CITY, Aug. 27, 2019 /PRNewswire/ -- Lipocine Inc. (NASDAQ:LPCN), a clinical-stage biopharmaceutical company focused on metabolic and endocrine disorders, announced today that the U.S. District Court of Delaware